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Background: Locoregional therapy is rarely the standard of care for De Novo stage IV breast cancer but usually
used for palliation of symptoms. This retrospective study aimed to determine whether surgery or radiation would
contribute to survival benefit for this group of patients by examining the survival outcome through the disease
molecular subtypes.
Materials and methods: We reviewed 246 patients with de novo stage IV (M1) breast cancer treated at our
hospital between 1990 and 2009. Multivariable Cox Analysis was used to evaluate the survival association with
subtypes and clinicopathologic factors.
Results: Patients with luminal-like subtype are mostly premonopausal (66.9%, P = 0.0002), with abnormal CA 15–3
level at initial diagnosis (58.7%, P = 0.01), a higher rate of bony metastases (78.5%, P = 0.02), and a lower rate of liver
metastases (22.3%, P < 0.0001). Patients with HER2-enriched and triple negative showed higher rate of nuclear grade
III, up to 35% and 40%, respectively (P = 0.01). There is no difference in treatment options patient received: systemic
chemotherapy up to 82.2 ~ 95% (p = 0.0705), locoregional treatment up to 40.0 ~ 51.2% (P-0.2571). The median overall
survival was 23.1 months: luminal-like subtype 39.6 months, HER2-enriched subtype 17.9 months, and triple negative
subtype 13.3 months, respectively (P < 0.0001). In multivariate analysis, poor prognostic factors included HER2-
enriched (HR 2.2, P < 0.0001) and triple negative subtype (HR 4.3, P < 0.0001), liver metastasis (HR 1.9, P < 0.0001),
lung metastasis (HR 1.4, P = 0.0153), and bone metastasis (HR 1.8, P = 0.0007). Subgroup analysis revealed that local
treatments (surgery or radiotherapy) to primary/regional tumors achieved better survival in patients with luminal-
like (3-year survival 66.4% vs. 34.4%, p = 0.0001) and HER2-enriched (3-year survival 41.6% vs. 8.8%, p = 0.0012)
subtypes, but not in triple negative subtype (P = 0.9575).
Conclusions: For better survival outcome, De Novo Stage IV breast cancer patients with luminal-like or HER2-
enriched subtype should be offered local treatments when surgery and/or radiotherapy presents an option for
proper control of the primary and regional tumors.Introduction
A number of retrospective data have shown that sub-
groups of women with de novo stage IV breast cancer
can attain long-term survival when their distant disease
is controlled and their primary tumors are treated.
Furthermore, although staged the same, women with de
novo breast cancer have superior outcome compared
with women with relapsed breast cancer – an indication* Correspondence: pengyu0907@gmail.com
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in any medium, provided the original work is pthat de novo breast cancer should be considered as a
separate entity entirely (Dawood et al. 2010). Although
only limited data linking the intrinsic breast tumor sub-
type to local treatment benefit for de novo stage IV
breast cancer is reported, the strong association between
breast cancer subtype and clinical outcome have been
pointed out in many studies, such as in ‘patients with
early stage breast cancer’ (Ali et al. 2000)’, ‘North American
women’ (O’Brien et al. 2010). Furthermore, it is a well
accepted fact that luminal subtype achieves better
prognosis among the breast cancer subtypes.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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molecularly distinct disorders according to gene-
expression profiling (Sotiriou & Pusztai 2009). However,
gene-expression profiling is not widespread use in clinical
settings up to the present. Most of us still use hormone re-
ceptor (HR) status and human epidermal growth factor
receptor-2 (HER2) as predictive and therapeutic markers
to select specific therapies for patients with breast cancer
(De Laurentiis et al. 2005).
Several retrospective studies have been cited on the
suggested strong association between locoregional therapy
and improvement of metastatic progression-free survival
and overall survival (Khodari et al. 2013). However, there
is few data to better define subgroups of patients who
would benefit from locoregional therapy, and thus the
wide variability in treatment choice always exists.
The question we posed to ourselves was: Does locoregi-
nal treatment for de novo stage IV breast cancer patients
have different outcome between different subtypes of
patients.
The current guideline in our hospital for the locore-
gional treatment decisions between palliative and cura-
tive for the de novo stage IV patients does not include
the molecular subtype as diagnostic factor. This study
aimed to determine whether significant survival benefit
could be added by locoregional therapy (surgical resec-
tion and/or radiation) in patients with de novo stage IV
breast cancer.
In this retrospective study, we divided the patients by
their intrinsic subtypes, i.e., hormone receptor (HR) andLum
Figure 1 Probability of OS for patients with vs. without local treatmehuman epidermal growth factor receptor-2 (HER2) status.
Based on these markers, breast cancer can be divided into
three major molecular subtypes: luminal-like (hormone
receptor positive, no HER2 over-expression), HER2-
enriched (HER2 over-expression), and triple negative
(hormone receptor negative & no HER2 over-expression).
The prognosis and clinical outcome from locoregional
treatments for de novo stage IV metastatic breast cancer
was analyzed.
Materials and methods
Patients with breast cancer treated between 1990 and
2009 in our hospital who met the following criteria were
included in this study: (1) de novo stage IV breast cancer
at initial diagnosis, (2) invasive carcinoma of the primary
breast tumor, (3) pathological confirmation of metastasis
to at least one site. Patients with the following condi-
tions were excluded: (1) prior treatment of systemic
chemotherapy or anti-hormonal therapy in other hospi-
tals, and/or (2) second malignancy.
All treatment decisions were made based on the Breast
Cancer Clinical Practice Guidelines developed in our
hospital in 1993 (Cheng et al. 2000), which are revised
annually, and in ways similar to the guideline developed
by the National Cancer Center Network (NCCN). All
clinical information of patients was collected prior to
treatment for a comprehensive Breast Cancer Data Base
in our hospital with approval from the Institutional
Review Board (IRB). Information collected in this data
base consists of (1) general data covering patientinal-like Subgroup
nt on Kaplan-Meier Method in Luminal-like Subgroup.
HER2-enriched Subgroup
Figure 2 Probability of OS for patients with vs. without local treatment on Kaplan-Meier Method in HER2-enriched Subgroup.
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history as well as specific, clinical, and treatment history;
(2) pathologic report on tumor tissues; (3) chemotherapy
information and related complications; (4) radiotherapy
information and related complications; (5) follow-up
information submitted every 6–12 months after the
completion of all treatments or at a tumor relapse; and
(6) late complication, if any.
SAS program was used for data input, data manage-
ment, data quality control, analysis and presentation. For
quality data control, our pathologists record pathological
information in the Pathology Report when surgical
specimens are available. The clinicians audit the charts
to ensure that the clinical information entered into the
Breast Cancer Data Base was accurate. All data entriesTriple-ne
Figure 3 Probability of OS for patients with vs. without local treatmeare done twice by two independent data processors. On-
line logic check is performed upon the first entry of all
data. Logic analysis between data forms and within each
form is performed regularly (Cheng et al. 2000).
The clinical risk factors, such as age at diagnosis,
primary tumor size, axillary lymph node status, nuclear
grade (Kronqvist et al. 1998), lymphovascular invasion
(LVI) (Schoppmann et al. 2004), hormonal receptor
status, human epidermal growth factor-2 (HER2) and
treatments were listed as variables for multivariable
analysis on the Cox proportional hazards model.
The Cox proportional hazards regression model was
fitted to examine the associations between treatment
type and survival (by molecular subtype, with vs. without
Locoregional therapy). Overall survival rate of eachgative Subgroup
nt on Kaplan-Meier Method in Triple-negative Subgroup.
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Method. Log-rank test and Chi-squared test were used
to assess the statistical significance.
Results
Follow-up and overall survival
A total of 246 patients with de novo stage IV breast cancer
with invasive carcinoma treated between 1990 and 2009
were included in this study with the last follow-up date of
December 31st 2011. The median follow-up interval was
21 months, and 32 months for 51 patients who were alive.Table 1 Patient and tumor characteristics by molecular subty
Luminal-like
(n = 121, 49.2%)
Age
> 40 94 (77.7%)








Nuclear Grade 1-2 24(19.8%)
Nuclear Grade 3 35 (28.9%)
unknown 62(51.3%)
Lymphovascular invasion




No axillary LN involvement 30 (24.8%)
Axillary, IM, or SC LN involvement 91(75.2%)
Tumor markers
Elevated CEA 53 (43.8%)
Elevated CA 15-3 71 (58.7%)






Systemic chemotherapy 106 (87.6%)
Anti-hormonal treatment 24 (19.8%)
Local treatment to primary breast tumor 62(51.2%)
*About whom information was known.The median overall survival for all 246 patients was
23.1 months; the median overall survival for patients with
luminal-like, HER2-enriched, and triple negative subtype
were 39.6, 17.9, and 13.3 months, respectively (P < 0.0001).
On the subgroup analysis, locoregional treatment for
primary breast tumor showed significant survival benefit
in patients with luminal-like (Figure 1, P = 0.0001) and
HER2-enriched (Figure 2, P = 0.0012) subtype. With
local treatment, the luminal-like patients achieved a 3-
year overall survival rate of 66.4% vs. 34.4% for those
without the local treatment (Figure 1); for the HER2 richpe
HER2 -rich Triple negative p
(n = 80 , 32.5%) (n = 45, 18.3%)
67(83.8%) 36 (80%) 0.5739
13(16.2%) 9 (20%)










19(23.8%) 8 (17.8%) 0.6284
61(76.2%) 37(82.2%)
40(50.0%) 15 (33.3%) 0.2740*
34(42.5%) 18 (40.0%) 0.0063
43(53.8%) 18 (40%) < 0.0001
34(42.5%) 18 (40%) 0.5189
13(16.3%) 8(17.8%) 0.6041
53(66.3%) 26 (57.8%) 0.0187
76(95.0%) 37 (82.2%) 0.0705
6(7.5%) 1 (2.2%) 0.0024
33(41.3%) 18(40.0%) 0.2571
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(Figure 2); and for the triple negative 6.7% with vs. 14.8%
without. In triple negative subtype, local treatment did not
improve outcome (Figure 3, P = 0.9575).
Special mentioning of the anti-HER2 treatment therapy
is needed here regarding the result from Figure 2. In the
twenty years between 1990 and 2009, the systemic chemo-
therapies for breast cancer have evolved more than once,
especially for HER2-directed therapies. Total number of
our patients who received anti-HER2 treatment is too
small to ascertain whether locoregional treatment still has
significant benefit after those who received anti-HER2
treatment. Nowadays, HER2-directed therapy is widely of-
fered, so for this particular subgroup of patients who get
better controlled of systemic disease, the benefit of locore-
gional treatment may need further investigation.
Clinical and pathological characters by subtype
Table 1 compares the clinical and pathological factors in
each subtype or, (compares the patient characteristics strati-
fied by the three subgroups). The majority of patients in all
three subgroups were older than 40 years old. Among the
luminal-like patients, 66.9% were premenopausal, which
was significantly higher than the HER2-enriched or triple
negative subtypes. Direct tumor invasion to chest wall from
primary tumor or inflammatory breast cancer (T4 and
non-T4 disease) did not stand out in any particular subtype
group. Patients with HER2-enriched or triple negative sub-





Triple negative 4.2 2.8-6.2
cT1-3 vs. cT4 0.7 0.5-0.9
NG 1–2 vs. NG 3 0.9 0.5-1.4
LVI
focal vs. no 0.6 0.3-1.4
Prominent vs. no 0.5 0.3-1.0
Lymph node involvement 1.1 0.8-1.5
CEA elevated vs. normal 1.1 0.8-1.5
CA 153 elevated vs. normal 1.1 0.8-1.4
Metastasis
Liver, yes vs. no 2.3 1.7-3.2
Lung, yes vs. no 1.7 1.3-2.2
Brain, yes vs. no 1.5 1.1-2.3
Bone, yes vs. no 1.3 0.9-1.8
*Local treatment, yes vs. no 0.5 0.4-0.6
Note: *Local treatment: surgery, radiotherapy, or both.tumor, up to 35% and 40% (p = 0.0092), respectively. The
percentages of prominent lymphovascular invasion of
primary breast tumor shown in the subtypes were close.
The same similarity was seen in the percentage of locore-
gional lymph node involvement. Patients with luminal-like
subtype had a higher elevation rate of CA 15–3 (58.7%,
p = 0.0063).
Luminal-like subtype patients had a lower rate of liver
metastasis (22.3%, p < 0.0001) and higher rate of bone me-
tastasis (78.1%, p = 0.0187). No significant difference was
seen in lung or brain metastasis among the subtype groups.
About the treatment options, more than eighty percent
of patients in each group underwent systemic chemother-
apy and up to 40 to 50 percent of patients underwent
locoregional treatment of primary tumor (p > 0.05). There
is no difference in treatment options patient received
among these three groups.
Univariate and multivariate analysis
Table 2 shows the univariate and multivariate analysis of
each clinicopathologic factors associated with overall sur-
vival. Both the univariate and multivariate analysis showed
that HER2-enriched and triple negative subtypes were sig-
nificantly associated with poor survival. Compared with
the luminal subtype patients, the HER2-enriched and
triple negative patients had poorer survival on univariate
analysis (HER2-enriched: HR 2.0, P < 0.0001; triple nega-
tive: HR 4.2, P < 0.0001) and also on multivariate ana-
lysis (HER2-enriched: HR 2.2, P < 0.0001; triple negative:ts on univariate and multivariate models
Multivariate
P HR 95% CI P
1
< 0.0001 2.2 1.5-3.1 < 0.0001








< 0.0001 1.9 1.4-2.5 0.0001
0.0004 1.4 1.1-1.9 0.0153
0.0256 1.3 0.9-1.9 0.1728
0.1016 1.8 1.3-2.5 0.0007
< 0.0001 0.6 0.4-0.8 0.0008
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conclusions illustrated on the Kaplan-Meier curves
(Figures 1,2 & 3).
Association between survival and factors such as the clin-
ical staging, locoregional lymph node involvement, nuclear
grade, status of lymphovascular involvement of primary
tumor, and level of initial tumor markers was not seen in
this study. Visceral organ metastasis, including liver, lung,
and brain, was an independent factor significantly associ-
ated with worse survival on univariate analysis. On multi-
variate analysis, visceral metastasis also showed a trend to
worse survival. Bone metastasis was not significantly associ-
ated with survival on univariate analysis but it was an inde-
pendent prognostic factor on multivariate analysis.
Patients undergoing locoregional treatment to primary
breast tumor, including surgical resection and/or radiation,
had better survival (HR 0.5, p < 0.0001). The status of
visceral organ metastasis may also be one of the deciding
factors when considering the locoregional therapy.Discussion
Based on our results, it seems reasonable to further
stratify the de novo stage IV breast cancer patients into
groups of different risk levels by hormone and HER2
status. Our data suggests the breast cancer subtype
should be included in decision criteria of local treatment
for patients with de novo stage IV breast cancer.
In this study, clinicopathologic factors, such as clinical
T stage, nuclear grade, status of lymphovascular infiltra-
tion, regional lymph node involvement, and level of
tumor markers, did not have impact on the treatment
outcome significantly. Most of these clinicopathologic
factors were known to associate with recurrence or pre-
diction of treatment response for early stage breast can-
cer (Corben 2013). For patients with de novo stage IV
status, these clinicopathologic factors may play a limited
role in managing the outcome.
Some limitations expected of most retrospective type
of study are noted here, such as selection bias. The ob-
servation presented here is based on the experience of a
single institution which may reflect the clinical routine
practice of our hospital only.
In summary, breast cancer is a group of molecularly
distinct neoplastic disorders. A multidisciplinary approach
combining systemic therapies with local treatment (surgery
or local radiation) in de novo stage IV patients with
luminal-like or HER2-enriched subtypes may not only
prevent local complications, but also prolong survival.Availability and requirements
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